1978PubMedRequires access

[The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].

M Jotzoff

Open publisher page 2 citations

Abstract

We report about the in-vitro-sensitivity tests of 1756 Enterobacteriaceae and Pseudomonas strains to amikacin, gentamicin, tobramycin and sisomicin. It was established, that amikacin is more effective than gentamicin, tobramycin and sisomicin in case of infections with Klebsiella, Proteus species, Psuedomonas strains and Enterobacter. The four aminoglycosides are well active against E. coli. Hospital acquired infections with Serratia are a domain of amikacin. Tobramycin is more effective than gentamicin and sisomicin against Pseudomonas infections. Amikacin is the drug of choice against gentamicin-resistent strains, which are also not infrequently resistant to other aminoglycosides. Resistance to gentamicin-tobramycin and gentamicin-tobramycin-sisomicin, is most frequent among Klebsiella strains. The cross-resistance rate is considerably higher among Enterobacteriaceae strains than among Pseudomonas species. The lowest rate of resistance (2.1%) and the high antimicrobial activity are the considerable advantages of amikacin.

About this research paper

What this paper is about

We report about the in-vitro-sensitivity tests of 1756 Enterobacteriaceae and Pseudomonas strains to amikacin, gentamicin, tobramycin and sisomicin. It was established, that amikacin is more effective than gentamicin, tobramycin and sisomicin in case of infections with Klebsiella, Proteus species, Psuedomonas strains and Enterobacter. The four aminoglycosides are well active against E. coli. Hospital acquired infections with Serratia are a domain of amikacin. Tobramycin is more effective than gentamicin and sisomicin against Pseudomonas infections. Amikacin is the drug of choice against gentamicin-resistent strains, which are also not infrequently resistant to other aminoglycosides. Resistance to gentamicin-tobramycin and gentamicin-tobramycin-sisomicin, is most frequent among Klebsiella strains. The cross-resistance rate is considerably higher among Enterobacteriaceae strains than among Pseudomonas species. The lowest rate of resistance (2.1%) and the high antimicrobial activity are the considerable advantages of amikacin.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We report about the in-vitro-sensitivity tests of 1756 Enterobacteriaceae and Pseudomonas strains to amikacin, gentamicin, tobramycin and sisomicin. It was established, that amikacin is more effective than gentamicin, tobramycin and sisomicin in case of infections with Klebsiella, Proteus species, Psuedomonas strains and Enterobacter. The four aminoglycosides are well active against E. coli. Hospital acquired infections with Serratia are a domain of amikacin. Tobramycin is more effective than gentamicin and sisomicin against Pseudomonas infections. Amikacin is the drug of choice against gentamicin-resistent strains, which are also not infrequently resistant to other aminoglycosides. Resistance to gentamicin-tobramycin and gentamicin-tobramycin-sisomicin, is most frequent among Klebsiella strains. The cross-resistance rate is considerably higher among Enterobacteriaceae strains than among Pseudomonas species. The lowest rate of resistance (2.1%) and the high antimicrobial activity are the considerable advantages of amikacin.

Key concepts: Sisomicin, Amikacin, Tobramycin, Gentamicin, Microbiology, Medicine, Aminoglycoside, Antimicrobial

Related papers

Back to paper searchBrowse research topicsOriginal source
[The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)]. — Research Paper | ScholarLens